Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

Hemi Pharma for Sale: “Hemi Pharma for Sale: Advanced Supplements for Peak Performance”

The pursuit of peak performance-whether in athletics, academics, or day-to-day life-has led to an increased demand for supplements that deliver more than just marginal gains. This is where Hemi Pharma for Sale steps in, offering a game-changing ...

USA Today Sports Media Group

5 Analysts Assess PROCEPT BioRobotics: What You Need To Know

5 Analysts Assess PROCEPT BioRobotics: What You Need To Know

In the last three months, 5 analysts have published ratings on PROCEPT BioRobotics (NASDAQ:PRCT), offering a diverse range of perspectives from bullish to bearish.

PTC Therapeutics Signs Exclusive Global License And Collaboration Agreement With Novartis; PTC To Receive Upfront Payment Of $1B, Up To $1.9B In Development, Regulatory And Sales Milestones

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NYSE:NVS), for its

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Eli Lilly (LLY) vs. Catalent (CTLT): Which Pharma Stock Offers Better Returns?

The pharma industry is evolving rapidly due to the ever-rising healthcare needs and increasing demand for customized medicine and treatments worldwide. So, let’s analyze Eli Lilly (LLY) and Catalent (CTLT), to determine which pharma stock offers better returns. Read more.

Wide Trading Range For Amgen Stock Makes This Option Shine

Even though Amgen is weak below the 200-day line, there's still a way to profit.

Investors Business Daily

3 Biotech Stocks with Promising Pipelines to Watch

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

3 Biotech ETFs for Diversified Innovation Exposure

Biotech ETFs provide the perfect balance of high-growth potential and diversified risk, offering investors access to healthcare breakthroughs. Given this backdrop, you might consider three biotech ETFs: iShares Biotechnology ETF (IBB), SPDR S&P Biotech ETF (XBI), and First Trust NYSE Arca Biotechnology Index Fund (FBT). Keep reading….

inkl

Read news from The Economist, FT, and more,
with one subscription

Telanagana: Spurious antibiotics worth Rs 1.33 crore seized from a pharmaceutical company

The drugs-control-administration">Drugs Control Administration, Telangana, seized a huge stock of antibiotics worth Rs 1.33 Crores from a manufacturing facility on Wednesday. Read further on Dynamite News:

Regeneron Pharmaceuticals Unusual Options Activity

Regeneron Pharmaceuticals Unusual Options Activity

Investors with a lot of money to spend have taken a bullish stance on Regeneron Pharmaceuticals (NASDAQ:REGN).

AMD Struggles Below Critical Levels: Can Market Share Growth Turn The Tide?

AMD Struggles Below Critical Levels: Can Market Share Growth Turn The Tide?

AMD stock faces bearish wave, below key moving averages with neutral RSI. Short-term rebound possible, but overall technicals and market share gains uncertain.

Biotech Leader ADMA Hits New Buy Point After Recovering From Surprise Plunge

Biotech Leader ADMA Hits New Buy Point After Recovering From Surprise Plunge

ADMA stock hit a new buy point in recent weeks after recovering from an unexpected plunge that sent shares below a key level.

Investors Business Daily

Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details

Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details

Roche agrees to acquire Poseida Therapeutics for $1.5 billion, expanding its CAR-T therapy platform with a focus on hematologic malignancies and solid tumors.

Milestone Scientific Secures Federal Supply Schedule Approval On Contract For CompuFlo Epidural System

Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced its approval on contract for the Federal Supply Schedule

4 Analysts Assess Enanta Pharma: What You Need To Know

4 Analysts Assess Enanta Pharma: What You Need To Know

In the last three months, 4 analysts have published ratings on Enanta Pharma (NASDAQ:ENTA), offering a diverse range of perspectives from bullish to bearish.

Get all your
news in one place.

100’s of premium titles.
One news app.

Why Poseida Therapeutics Shares Are Trading Higher By 219%; Here Are 20 Stocks Moving Premarket

Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) rose sharply in today's pre-market trading after the company agreed to be acquired by Roche in a $1.5 billion deal.

AIM ImmunoTech Issues Presentation Detailing Case For Re-Electing Current Directors To Oversee Continued Momentum And Drive Strategy To Create Long-Term Value For Patients And Shareholders; Warns Shareholders Of Its Belief That The Activist Group And Its Nominees Have A Self-Interested Agenda And Could Put AIM's Clinical Progress At Risk

Highlights How Positive Data in AIM's Clinical Pipeline and Big Pharma Partnerships are Positioning the Company for Commercialization Opportunities in High-Value Indications Including Pancreatic CancerWarns Shareholders

A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 13 Analysts

Rhythm Pharmaceuticals (NASDAQ:RYTM) has been analyzed by 13 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.

Analyst Expectations For Sarepta Therapeutics's Future

14 analysts have expressed a variety of opinions on Sarepta Therapeutics (NASDAQ:SRPT) over the past quarter, offering a diverse set of opinions from bullish to bearish.

Get all your
news in one place.

100’s of premium titles.
One news app.

I love the ingenious design of this women’s health brand logo

Design Bridge and Partners create a pioneering brand for the future.

Investors Business Daily

AbbVie Jumps 5% On An Upgrade Despite Bristol Myers-Tied Setback

AbbVie stock popped Friday after an analyst upgraded it on the remaining opportunity for its Cerevel takeover despite a huge misstep.

Democrats can still lower drug prices

High medication costs are a common enemy for Democrats, Republicans and patients. There's still time to fight

Investors Business Daily

Amgen Stock Has High Implied Volatility. An Iron Condor Takes Advantage.

With the recent spike in implied volatility, an iron condor on Amgen can use short strikes with a wide profit range.

International Business Times

Lilly Sues US Agency For Blocking Proposed Drug Rebate Plan

Eli Lilly is taking the HRSA to court for allegedly blocking the pharma's discount plan.

FDA Implements New Rules For Drug Advertisements

New FDA guidelines enhance transparency in TV drug ads by requiring clearer risk information and neutral presentation of side effects.

Investors Business Daily

Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics

Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.

People

Kritika SarmahHer

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Medical Pharmaceuticals

Cantor Fitzgerald

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

261,421 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play